SCHEMBL4873208

SCHEMBL4873208

Nc1cccc(-c2ccc3cc(-c4c(C5CCCCC5)c5sc(C(=O)O)cc5n4CC(=O)N4CCC(N5CCOCC5)CC4)ccc3n2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBX7 O95931 2/20 0.35
CDYL2 Q8N8U2 2/20 0.35
CDYL Q9Y232 2/20 0.35
CDY1; CDY1B Q9Y6F8 2/20 0.35
ACHE P22303 1/20 0.35
IRAK4 Q9NWZ3 2/20 0.33
SMO Q99835 1/20 0.33
GAA P10253 2/20 0.33
POLB P06746 1/20 0.33
TSHR P16473 1/20 0.33
MTOR P42345 1/20 0.32
ACACB O00763 1/20 0.32
ACACA Q13085 1/20 0.32
ALDH1A1 P00352 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
KDM4E B2RXH2 1/20 0.31
TACR2 P21452 1/20 0.31
TACR3 P29371 1/20 0.31
SCN9A Q15858 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4878001 0.91 ALDH1A1 (0.34) SMOGAAALDH1A1KMT2ASMN1; SMN2
SCHEMBL4873982 0.91 GRIN1 (0.39) CBX7CDYL2CDYLCDY1; CDY1BACHE
SCHEMBL4878172 0.91 PIK3CA (0.39) CBX7CDYL2CDYLCDY1; CDY1BACHE
SCHEMBL4873226 0.91 CBX7 (0.39) CBX7CDYL2CDYLCDY1; CDY1BACHE
SCHEMBL4876257 0.89 ALDH1A1 (0.34) SMOGAAALDH1A1KMT2ASMN1; SMN2
SCHEMBL4877773 0.88 CBX7 (0.38) CBX7CDYL2CDYLCDY1; CDY1BACHE
SCHEMBL4877238 0.88 ALDH1A1 (0.33) SMOGAAALDH1A1KMT2ASMN1; SMN2
SCHEMBL4870793 0.88 CBX7 (0.37) CBX7CDYL2CDYLCDY1; CDY1BACHE
SCHEMBL4877126 0.88 CBX7 (0.37) CBX7CDYL2CDYLCDY1; CDY1BACHE
SCHEMBL4872058 0.87 GAA (0.40) CBX7CDYL2CDYLCDY1; CDY1BACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 CBX7 2500/4885CDYL2 4283/4885CDYL 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.